SUTRO BIOPHARMA, INC. Earnings Per Share Diluted

• SUTRO BIOPHARMA, INC. showed an increase of +23.5% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2019: $0.60 (loss) per share | Q3 2019: $0.56 (loss) per share | Q2 2020: $0.94 per share | Q3 2020: $0.45 per share | Q2 2021: $0.13 (loss) per share | Q3 2021: $0.67 (loss) per share | Q1 2022: $0.84 (loss) per share | Q2 2022: $0.55 (loss) per share | Q3 2022: $0.37 (loss) per share | Q1 2023: $0.85 (loss) per share | Q2 2023: $0.64 (loss) per share | Q3 2023: $0.81 (loss) per share | Q1 2024: $0.59 (loss) per share | Q2 2024: $0.59 (loss) per share | Q3 2024: $0.59 (loss) per share | Q1 2025: $0.91 (loss) per share | Q2 2025: $0.14 (loss) per share | Q3 2025: $0.67 (loss) per share.
• Over the full 6 years of available data (2020 to 2025), SUTRO BIOPHARMA, INC.'s Earnings Per Share Diluted has declined by 2,171.7%.
• Historical annual values: Fiscal year 2025: $22.49 (loss) per share | Fiscal year 2024: $29.40 (loss) per share | Fiscal year 2023: $1.78 (loss) per share | Fiscal year 2022: $2.35 (loss) per share | Fiscal year 2021: $2.29 (loss) per share | Fiscal year 2020: $0.99 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026